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We conducted a prospective, randomized study to compare conventional continuous venovenous hemodiaﬁltration (CVVHDF)
with sustained hemodiaﬁltration (SHDF) using an acetate-free dialysate. Fifty critically ill patients with acute kidney injury
(AKI) who required renal replacement therapy were treated with either CVVHDF or SHDF. CVVDHF was performed using a
conventional dialysate with an eﬄuent rate of 25mL·kg−1 · h−1, and SHDF was performed using an acetate-free dialysate with a
ﬂow rate of 300−500mL/min. The primary study outcome, 30d survival rate was 76.0% in the CVVHDF arm and 88.0% in the
SHDF arm(NS).Boththe number ofpatientswho showedrenal recovery (40.0%and68.0%,CVVHDF andSHDF,resp.; P<. 05),
and the hospital stay length (42.3 days and 33.7 days, CVVHDF and SHDF, resp.; P<. 05), signiﬁcantly diﬀered between the two
treatments. Althoughthetotal convective volumesdid notsigniﬁcantlydiﬀer,thedialysateﬂowrate washigherandmeanduration
of daily treatment was shorter in the SHDF treatment arm. Our results suggest that compared with conventional CVVHDF, more
intensive renal support in the form of post-dilution SHDF with acetate-free dialysate may accelerate renal recovery in critically ill
patients with AKI.
1.Introduction
Despiteimprovedmedicalcare,themortalityrateincritically
ill patients with acute kidney injury (AKI) who require
renal replacement therapy (RRT) is still high (>50%) [1–5].
Whether or not more intensive RRT improves the outcomes
of patients with AKI is an ongoing debate; several studies
have reported the beneﬁts of frequent dialyses and/or high-
dose regimens [6, 7], while others have reported no such
beneﬁt [8, 9]. The multicenter, prospective, randomized
US Veterans Aﬀairs/National Institutes of Health (VA/NIH)
AcuteRenalFailure Trial Network study recently investigated
this issue and is the largest trial in this ﬁeld to date [10]. The
study found no signiﬁcant diﬀerence between the intensive
and less-intensive treatment groups with regard to death
rate by day 60, duration of RRT, rate of recovery of kidney
function, rate of nonrenal organ failure, or proportion
of patients who developed hypotension that required the
discontinuation of one or more RRT modalities. Thus,
there were no signiﬁcant diﬀerences in the beneﬁts of
intermittent hemodialysis (IHD), sustained low-eﬃciency
dialysis (SLED),high-dose (35mL·kg−1·h−1) CVVHDF,and
standard-dose (20mL·kg−1·h−1) CVVHDF.
We previously tested the hypothesis that more intensive
RRT decreases mortality among critically ill patients with
AKI to a greater extent than SLED or IHD [11]. In order
to achieve clearance of small and medium molecular weight
solutes, we tested a modiﬁed IHD protocol which we termed
sustained hemodiaﬁltration (SHDF). SHDF is a form of2 International Journal of Nephrology
intermittent hemodiaﬁltration (IHDF) with extended (6–
10h) sessions, and regular blood and dialysate ﬂow rates of
200mL/min and 500mL/min, respectively. In addition, the
replacement ﬂuid in SHDF is infused postﬁlter. The results
of that study suggested that compared with conventional
continuous RRT (CRRT) including high-dose CVVHDF,
more intensive renal support in the form of postdilution
SHDFcould decrease mortality and accelerate renal recovery
in critically ill patients with AKI.
Themajorityofmaintenancehemodialysis(HD)patients
in Japan are currently treated using an acetate-containing
bicarbonate dialysate (acetate dialysate) with an acetate
concentration of 48 to 60mg/dL (8 to 10mmol/L). Acetate
may induce the production of cytokines and dilatation
of vessels, but a small amount of acetate is necessary to
maintain the pH of the dialysate at 7.1 to 7.6 to prevent
precipitation of calcium and magnesium [12–14]. Although
patients with acetate intolerance normally require acetate-
free bioﬁltration, the standard dialysate still includes acetate.
Therefore, critically ill patients with AKI who required acute
RRT have been treated with acetate-containing dialysate.
In the USA, although citrate dialysates (Citrasate
￿ and
DRYalysate
￿, Advanced Renal Technologies Co. Ltd, USA)
may be used for maintenance of HD patients or critically ill
RRTpatients,thoseformulationsstillincludeasmallamount
of acetate [15]. Citrate dialysates are also commonly used
as anticoagulants in cases when heparin cannot be utilized,
such as in heparin-induced thrombocytopenia (HIT), high
bleeding risk, trauma, and impending/postsurgical proce-
dure, or in order to prevent the hemoﬁlter clotting. Recently,
thecompletelyacetate-free bicarbonatedialysate Carbostar
￿
(Ajinomoto Pharma, Tokyo, Japan) became available in
Japan. However, as yet there are no reports which investigate
the eﬃcacy of acetate-free bicarbonate dialysate in critically
ill patients with AKI.
In order to determine the impact of acute RRT strate-
gies on patient outcomes, we conducted a prospective,
randomized study comparing postdilution CVVHDF with
an eﬄuent rate of 20 to 25mL·kg−1·h−1, with postdi-
lution SHDF performed on a daily basis. Since there
were no signiﬁcant diﬀerences in the beneﬁts aﬀorded by
high-dose (35mL·kg−1·h−1) CVVHDF and standard-dose
(20mL·kg−1·h−1) CVVHDF in the largest previous ATN
trial [10], CVVHDF was performed with the standard dose.
CVVHDF was performed using acetate-containing dialysate
and replacement ﬂuid, and SHDF was performed using
acetate-free dialysate.
2.Subjectsand Methods
2.1. Study Design. This study was conducted in accordance
with the Declaration of Helsinki (1996 amendment) and
was performed at the Intensive Care Unit (ICU) of Nihon
University Nerima Hikarigaoka Hospital, Tokyo, Japan, with
the approval of the Clinical Research Ethics Committee
of the same institution. All participants or their family
members provided written informed consent prior to the
commencement of the study. This study was designed
speciﬁcally for critically ill patients with AKI. All patients
were admitted to the ICU of our hospital between April2008
and October 2010. A total of 50 patients who had developed
AKI that required RRT in the ICU were eligible for inclusion
in this study. The main criterion for inclusion was a clinical
diagnosisofAKI,deﬁnedbyatleastoneofthefollowing con-
ditions: (1) volumeoverload despite diuretic administration,
(2) oliguria (urine output <200mL/12h) in spite of ﬂuid
resuscitation and diuretic administration, (3) anuria (urine
output <50mL/12h), (4) azotemia (blood urea nitrogen
>80mg/dL), (5) hyperkalemia (K value > 6.5mEq/L), or
( 6 )c l a s s i ﬁ c a t i o nu n d e rt h e“ R , ”“ I , ”o r“ F ”c a t e g o r i e so f
the Risk, Injury, Failure, Loss, and End-stage kidney disease
(RIFLE) classiﬁcation system [16]. The exclusion criteria
for this study were the presence of end-stage renal disease
requiring IHD, advanced chronic kidney disease (CKD)
stages 4and5 (deﬁnedas estimated glomerular ﬁltration rate
(eGFR) <30mL/min/1.73m2) before admission, previous
kidney transplant, an anticipated ICU stay of less than 48h,
or inability to provide informed consent. Severity of illness
and hemodynamic instability were not used as exclusion
criteria. All thepatientswere followed prospectively from the
time of enrollment through discharge.
The type of treatment, eﬀective duration of treatment,
volume of ultraﬁltrate and replacement ﬂuid, episodes of
hemoﬁlter clotting, and number of episodes of catheter
dysfunction were recorded for each treatment day. Acute
Physiology and Chronic Health Evaluation (APACHE) II
scores [17] andSequentialOrgan FailureAssessment (SOFA)
scores [18] were obtained at the time of initiation of RRT.
The presence of pre-existing chronic kidney disease stage 3
was deﬁned by a premorbid estimated glomerular ﬁltration
rate (eGFR) of 30–60mL·min−1·1.73m−2.T h ee G F Rf o r
Japanese patients was calculated using the following formula
[19]: eGFR (mL·min−1·1.73m−2) = 194 × sCr−1.094 ×
Age−0.287 (×0.739 for women), where sCr was the serum
creatinine concentration. Pre-ICU sCr values were used
to calculate the proportion of patients who fulﬁlled the
RIFLE categories of risk, injury, and failure at the time
of ICU admission. Sepsis was diagnosed clinically by the
attending clinician using published consensus criteria [20].
The indicators of kidney function (sCr, serum urea nitrogen,
and urine output) were documented on ICU admission, on
study enrollment, and on ICU and hospital discharge.
2.2. Treatment Assignments. On the initiation of RRT,
the patients were randomly assigned to the CVVHDF or
SHDF treatment arms by a computer-generated adaptive
randomization scheme. An independent investigator, who
had neither treated nor was aware of the proﬁle of the
subjects before the commencement of the trial, monitored
randomization in the order of the entry of the subjects;
then the particulars of the assignments were immediately
delivered to the individual investigators. To ensure balanced
randomization, the treatment assignments were stratiﬁed by
sepsis and oliguria, because both of these parameters are
independent predictors of patient survival [1, 21]. We usedInternational Journal of Nephrology 3
the following stratiﬁcation categories: (1) sepsis + oliguria,
(2) sepsis + nonoliguria, (3) nonsepsis + oliguria, and (4)
nonsepsis + nonoliguria.
Each patient was treated for 2 or more consecutive
days. Heparin or nafamostat mesilate was used as the
anticoagulant in all patients at doses of 6–13U·kg−1·h−1
and 0.4–0.6mg·kg−1·h−1, respectively. Vascular access was
obtained by placing temporary dual-lumen catheters in
the femoral or internal jugular vein. Hemoﬁlters with a
1.0m2 polymethylmethacrylate (PMMA; Hemofeel CH-1.0;
Toray,Tokyo,Japan) orpolyester-polymer alloy(PEPA;FDY-
100GW;Nikkiso,Tokyo,Japan) membranewereusedinboth
treatment arms.
All medications and nutrition were ordered and admin-
istered by the primary caregivers in the ICU, who did not
actively participate in the study. Interventions to maintain
hemodynamic stability, including adjustment of ultraﬁltra-
tion,administration ofsalineﬂushes,coolingofthedialysate,
and sodium modeling, were performed as required. The
requirement of pressor support was determined according to
the status of the patient during each RRT session.
2.3. CVVHDF. CVVHDF was performed using Asahi ACH-
10 hemodiaﬁltration equipment (Asahi Kasei Medical Co.,
Tokyo, Japan). Hemodiaﬁltration was accomplished using
blood ﬂow rates of 80–200mL/min and postdilution admin-
istration of replacement ﬂuid. Sublood-BS
￿ (Fuso Pharma-
ceutical Industries Ltd., Osaka, Japan), a sterile bicarbon-
ate solution containing acetate, was used as the dialysate
and replacement ﬂuid for CVVHDF. The ultraﬁltrate was
adjusted to achieve ﬂuid balance in each patient, and ﬂuid
replacement and net ultraﬁltration rates varied with the
clinical status of the patient. In the CVVHDF modality,
the “total convective rate” represents the product of the
convective components, that is, the sum of the replacement
ﬂuid rate and the ﬂuid removal rate, and does not include
the rate at which dialysate is spent. The “total convective
volume” represents the sum of the replacement ﬂuid volume
and the ﬂuid removal volume. The actual delivered dosage,
or total eﬄuent ﬂow rate (mL/kg/h), is the sum of the
replacement ﬂuid rate, ﬂuid removal rate, and dialysate ﬂow
rate.CVVHDFwasprescribed toprovideatotaleﬄuentﬂow
rate of 25mL·kg−1·h−1, based on the patient’s weight before
the onset of acute illness. This dosage was adjusted for body
weight changes and hemodynamic instabilities throughout
the treatment period. Every attempt was made to divide
the rate of ﬂow of the sterile bicarbonate solution equally
between the replacement ﬂuid rate and dialysate ﬂow rate.
The total time of actual CVVHDF treatment (min/24h) was
recorded daily, along with time spent on treatment of clots,
procedures, or other events. The hemoﬁlters were replaced
every 24h. Arterial blood gas analysis was performed
before (post) and after (pre) hemoﬁlter replacement at each
treatment session.
2.4. SHDF. SHDF was performed with the Nikkiso DBB-02
(Nikkiso Co., Tokyo, Japan). All patients underwent SHDF
during the daytime in the ICU for 6–8h. The acetate-free
Table 1: Renal replacement therapy procedures.
CVVHDF SHDF
RRT equipment ACH-10 DBB-02
RO equipment — NRX-20P
PURESYSTEM
Hemoﬁlter PMMA,
PEPA PMMA, PEPA
Dialysate Sublood-BS
￿ Carbostar
￿
Replacement ﬂuid Sublood-BS
￿ Sublood-BS
￿
Blood ﬂow rate (mL/min) 80–200 80–200
Dialysate ﬂow rate (mL/h) 300–2000 300–500
Replacement ﬂuid rate (mL/h) 300–3000 300–3000
CVVHDF: continuous venovenous hemodiaﬁltration; PEPA: polyester-
polymer alloy; PMMA: polymethylmethacrylate; RO: reverse osmosis; RRT:
renal replacement therapy; SHDF: sustained hemodiaﬁltration.
bicarbonate dialysate (Carbostar
￿) was prepared in the ICU
using reverse osmosis equipment (NRX-20P PURESYSTEM;
Daicen Membrane-Systems Ltd., Tokyo, Japan). SHDF was
accomplished using blood ﬂow rates of 80–200mL/min
and postdilution administration of replacement ﬂuid. The
initial dialysate ﬂow rate was 300mL/min, and if the
patients were hemodynamically stable, this was increased
to 500mL/min. Sublood-BS
￿ was used as the replacement
ﬂuid for SHDF. The ultraﬁltrate was adjusted to achieve
ﬂuid balance in each patient, and the ﬂuid replacement and
net ultraﬁltration rates varied with the clinical status of the
patient. Target replacement ﬂuid volume was set to greater
than 14 L/session, and SHDF was performed until this target
was achieved. In the SHDF modality, the “total convective
rate” represents the product of the convective components,
that is, the sum of the replacement ﬂuid rate and the ﬂuid
removal rate. The “total convective volume” represents the
sum of the replacement ﬂuid volume and the ﬂuid removal
volume. The total SHDF treatment time was recorded daily,
along with time spent on the treatment of clots, procedures,
or other events. Arterial blood gas analysis was performed
before (pre) and after (post) each treatment.
RRT procedures and composition of acetate-free
dialysate (Carbostar
￿) and sterile bicarbonate solution
(Sublood-BS
￿) are listed in Tables 1 and 2, respectively.
Patients in both treatment arms were transitioned to
conventional IHD at the discretion of the treating nephrol-
ogists. This usually occurred when the patient was still
dependentondialysisbuthad beentransferred fromtheICU
to the ward, or when the patient was being mobilized in
the ICU. The dosage and timing of IHD were determined
by the treating nephrologists. Renal recovery was deﬁned on
the basis of Cr clearance, measured by 6-hour timed urine
collections when urine ﬂow increased to more than 30mL/h
or when there was a spontaneous fall in the sCr level. RRT
was continued if the Cr clearance was less than 12mL/min
and was discontinued if the Cr clearance was greater than
20mL/min; decisions regarding discontinuation of RRT for
subjects with intermediate values of Cr clearance were left to
the investigator.4 International Journal of Nephrology
Table 2: Composition of acetate-free dialysate (Carbostar
￿)a n d
sterile bicarbonate solution(Sublood-BS
￿).
Acetate-free
dialysate
Sterile
bicarbonate
solution
Sodium (mEq/L) 140 140
Chloride (mEq/L) 111 111.5
Calcium (mEq/L) 3 3.5
Magnesium (mEq/L) 1.0 1.0
Potassium (mEq/L) 2.0 2.0
Glucose (mg/dL) 150 100
Bicarbonate (mEq/L) 35 35
Acetate (mEq/L) 0 0.5
Citrate (mg/dL) 12.8 0
Final pH 7.5–8.0 7.2–7.4
Osmolarity (mOsm/kg) 298 298
2.5. Outcome Measurements. The primary outcome measure
was survival until discharge from the ICU or for 30d,
whichever was earlier. Secondary end points included renal
recoveryatthetimeofdischargefromtheICU,renalrecovery
at the time of discharge from the hospital, ICU survival,
hospital survival, length of ICU stay, and length of hospital
stay.
2.6. Statistical Analysis. Data were expressed as mean ± SD.
Analyses were performed on an intention-to-treat basis. The
primary analysis was the comparison of the proportion of
patientsineachstudyarmwho surviveduntildischarge from
the ICU or for 30d, whichever was earlier. The proportions
were compared using Pearson’s χ2 test, or Fisher’s exact test
when the χ2 test was not valid. The secondary analysis was
the comparison of the following parameters between the two
studyarms: proportionofpatientswho recoveredrenal func-
tion at the time of discharge from the ICU and hospital, ICU
s u r v i v a l ,h o s p i t a ls u r v i v a l ,a n d length of hospital stay. The
methods used to perform these comparisons were similar to
those used in the primary analysis. Baseline characteristics
and outcome measures were compared using the two-group
t-test or Wilcoxon’s rank-sum test for continuous variables
and Pearson’s χ2 test or Fisher’s exact test for categorical
variables.
The Kaplan-Meier method was used to estimate the
hospitalsurvivalfortheprescribedRRT,andthelog-ranktest
was used to compare the survival curvesofthe two therapies.
All statistical tests were two sided and were performed using
as i g n i ﬁ c a n c el e v e lo fP<. 05.
3.Results
A total of 50 patients were enrolled in the study and were
randomly assigned to each treatment arm. The demographic
data and clinical characteristics of the patients in the two
arms are presented in Table 3. The baseline characteristics
did not signiﬁcantly diﬀer between the two arms. In all,
18 patients were included in the sepsis + oliguria stratum,
7 in the sepsis + nonoliguria stratum, 12 in the nonsepsis
+ oliguria stratum, and 13 in the nonsepsis + nonoliguria
stratum. Theproportionof patientswitholiguria,sepsis, and
preexisting chronic kidney disease (deﬁned as premorbid
eGFR <60mL·min−1·1.73m−2) was similar for both treat-
ment arms.
T h eR R Tp a r a m e t e r sa r ed e s c r i b e di nTable 4.T h e
number of treatments performed per patient was not
signiﬁcantly diﬀerent between the two arms. The number
of treatment hours per day was signiﬁcantly less in the
SHDF arm than in the CVVHDF arm. The dialysate ﬂow
rate and total dialysate volumes were signiﬁcantly higher
in the SHDF arm (dialysate volume, 9.6 ± 1.6L/session in
the CVVHDF arm versus 189 ± 28L/session in the SHDF
arm; P<. 0001). The total convective rate was higher in the
SHDF arm than in the CVVHDF arm; however, because the
duration ofSHDFtreatment was shorter, the totalconvective
volumes were not signiﬁcantly diﬀerent between the two
groups. Accounting for the eﬀect of postdilution ﬂuid
replacement on solute clearance, the mean actual delivered
dosage was 26.6mL·kg−1·h−1 in the CVVHDF arm. There
were instances in which RRT was interrupted by hemoﬁlter
thrombosis and catheter dysfunction; interruptions were
observed signiﬁcantly more frequently during CVVHDF
(30.1% of sessions) than during SHDF (12.6% of sessions;
P<. 05). In 20 of the 203 CVVHDF treatments (9.8%),
hypotension occurred that required discontinuation of the
treatment (versus 12 of the 170 SHDF treatments [7.1%],
P = .32). In 26 of the CVVHDF treatments (12.8%),
initiation of vasopressor support was required (versus 18 for
SHDF [10.5%], P = .48), and in 63 of the CVVHDF treat-
ments (31.0%), other interventions were required because
of treatment-associated hypotension (versus 44 for SHDF
[25.8%], P = .19). As shown in Figure 1,t h ep Ha n d
HCO3
− concentration of arterial blood was signiﬁcantly
increased after treatment compared to pretreatment in
both arms. However, comparing between the two arms,
pH and HCO3
− concentration were higher in the SHDF
arm compared to the CVVHDF arm both before and after
treatment.
Although the length of ICU stay was not signiﬁcantly
diﬀerent between the two arms, the length of hospital stay
wassigniﬁcantlyshorterintheSHDFarmthantheCVVHDF
arm (Table 5). The primary study outcome, survival until
discharge from the ICU or for 30d, whichever was earlier,
was 76.0% in the CVVHDF arm and 88.0% in the SHDF
arm (no signiﬁcant diﬀerence). There was no signiﬁcant
diﬀerence in the ICU survival rate and hospital survival rate
between the two arms (Figure 2). However, the total number
of patients who showed renal recovery was signiﬁcantly
higher in the SHDF arm than in the CVVHDF arm,
and signiﬁcant diﬀerences were detected in the number of
surviving patients showing renal recovery at the time of
discharge from the ICU or from the hospital (Table 5). In
addition, 16% of patients in the CVVHDF arm and 8% of
those in the SHDF arm were transitioned to IHD while in
the ICU (no signiﬁcant diﬀerence).International Journal of Nephrology 5
Table 3: Baseline characteristics of patients.
Characteristic CVVHDF SHDF P value
No. of patients (male/female) 25 (17/8) 25 (16/9) NS
Age (years) 65.3 ± 13.1 66.5 ± 12.1 NS
Cause of acute kidney injury (%) NS
Nephrogenic 20 24
Sepsis 52 48
Cardiogenic 12 12
Postsurgical 8 8
Drug induced 0 4
Hepatic failure 4 4
Other 4 0
Presence of CKD on admission (%) 40 44 NS
APACHE II score 19.6 ± 3.7 20.0 ± 4.3 NS
SOFA score 8.1 ± 2.0 8.2 ± 3.2 NS
RIFLE classiﬁcation
R (%) 20 20 NS
I (%) 44 40 NS
F (%) 36 40 NS
Mechanically ventilated (%) 36 32 NS
Oliguric (%) 60 60 NS
Baseline systolic blood pressure (mmHg) 107 ± 32 110 ± 29 NS
Required vasopressors (%) 28 24 NS
Renal parameters at RRT initiation
Serum urea nitrogen (mg/dL) 69 ± 26 68 ± 24 NS
Serum creatinine (mg/dL) 4.6 ± 2.3 4.8 ± 2.1 NS
Days from ICU admissionto RRT 2.1 ± 1.3 2.1 ± 1.5 NS
APACHE:acute physiology and chronic health evaluation; CKD: chronic kidneydisease;CVVHDF: continuousvenovenous hemodiaﬁltration; ICU: intensive
care unit; RIFLE: Risk, Injury, and Failure with the outcome classes Loss and End-stage kidney disease classiﬁcationsystem; RRT: renal replacement therapy;
SOFA: sequentialorgan failure assessment;SHDF: sustained hemodiaﬁltration.
Table 4: RRT characteristics by treatment group.
Characteristic CVVHDF SHDF P value
Total number of treatment days/sessions 203 170 —
Mean treatment times (days or sessions) per patient 8.1 ± 3.5 6.6 ± 2.6 NS
Mean duration of daily treatment (h) 15.2 ± 3.8 6.0 ± 1.0 <.0001
Dialysate ﬂow rate (mL/min) 10.8 ± 2.8 471 ± 27 <.0001
Total dialysate ﬂow volume (L/session) 9.6 ± 1.6 169 ± 28 <.0001
Total convective rate (mL/h) 683 ± 159 2006 ± 826 <.0001
replacement ﬂuid rate (mL/h) 549 ± 127 1696 ± 819 <.0001
ﬂuid removal rate (mL/h) 134 ± 58 310 ± 70 <.0001
Total convective volume (L/session) 15.0 ± 4.5 12.0 ± 5.1 NS
Actual delivered dosage (mL/kg/h) 26.6 — —
CVVHDF: continuous venovenous hemodiaﬁltration; RRT: renal replacement therapy; SHDF: sustained hemodiaﬁltration.
4.Discussion
We propose that the acetate-free dialysate may have
improved circulatory dynamics during RRT due to the
diﬀerences in glucose and bicarbonate levels from standard
dialysate, a direct eﬀect of citrate, and the absence of
acetate in the dialysate. Acetate can induce the production
of nitric oxide, a vasodilator [22]t h a tc a nc a u s ei n t r a -
dialytic cardiovascular instability [23, 24], and therefore
elevated acetate load might lead to hemodynamic instability.
Following treatment with acetate-free dialysate, we found
a signiﬁcant increase in pH and HCO3
− concentration,
and these levels were signiﬁcantly higher after treatment in
the SHDF arm than in the CVVHDF arm. There was no
signiﬁcant diﬀerence in the requirement for vasopressors
during RRT between the two groups.
Therefore, in contrast to CVVHDF, SHDF may be suita-
bleforbothhemodynamically stableand unstablesubjects.It6 International Journal of Nephrology
Table 5: Outcome by treatment group.
Characteristic CVVHDF SHDF P value
Total ICU days 18.8 ± 11.1 14.1 ± 7.2 NS
Total hospital days 42.3 ± 18.8 33.7 ± 18.8 <.05
Survival until discharge
from ICU or for 30d (%) 76 88 NS
ICU survival (%) 72 84 NS
Hospital survival (%) 64 80 NS
ICU renal recovery (%)
All patients 20 44 <.05
Survivors 27.8 52.3 <.05
Hospital renal recovery (%)
All patients 40 68 <.05
Survivors 62.5 85 <.05
CVVHDF: continuous venovenous hemodiaﬁltration; ICU: intensive care
unit; SHDF: sustainedhemodiaﬁltration.
is diﬃcult to ascertain whether this ﬁnding can be attributed
to the use of dialysate “without” acetate, which might cause
vasodilation and hypotension, since we could not measure
bloodacetate concentrationsin the present study tocompare
the two dialysates. Further studies would be needed to clarify
the eﬃcacy of completely acetate-free dialysate. Acetate-free
dialysate has several advantages. Rapid correction of acidosis
is possible because of the greater bicarbonate concentration.
Also,acetate-freedialysatecontains12.8mg/dL(667μmol/L)
of citrate instead of acetate to adjust the pH. Citrate has a
long history of use in medicine as an anticoagulant and has
the ability to chelate calcium ions. The half-life of citrate
is very short, allowing it to be rapidly metabolized by the
liver. Indeed, the successful use of citrate dialysate in liver
transplant patients and in high bleeding risk patients has
been reported [15]. These advantages suggest that acetate-
free dialysate may be suitable for critically ill patients with
AKI, without precipitating metabolic acidosis. Although
CVVHDFwas continuedfor15.2h,the pHleveland HCO3
−
concentration following CVVHDF treatment were similar
to pre treatment in the SHDF arm. In the SHDF arm,
diﬀusive transport was engendered by a dialysate ﬂow rate
of 471mL/min, with an extended session duration (6.0h).
SHDF convective transport was characterized by post-ﬁlter
infusion of replacement ﬂuid and a total eﬄuent volume of
12.0L/session, which was not signiﬁcantly diﬀerent from the
CVVHDF arm. Therefore, SHDF showed superior eﬃcacy
of diﬀusive transport and equivalent eﬃcacy of convective
transport to those reported in previous studies that used
“more intensive CRRT.”
The present study has several limitations. Firstly, our
study was performed on a small number of patients and
was a single-center study. A randomized, prospective trial
comparing SHDF with conventional CRRT in a large cohort
of patients is necessary to determine the relative impact
of SHDF on mortality. Secondly, severity as assessed by
APACHE II and SOFA scores in our patients was mild
compared to other trials because subjects with nephrogenic
AKI, including acute tubular necrosis (ATN), were included,
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Figure 1: Changes in arterial blood pH and HCO3
− concentration
before and after treatment in the two treatment arms. ∗P<. 01,
∗∗P<. 001 versus CVVHDF.
and so the survival rate was very high even in the CVVHDF
arm.Thirdly,16%ofpatientsintheCVVHDFarmand8%of
those intheSHDFarm were transitioned toIHDwhile in the
ICU (no signiﬁcant diﬀerence). Therefore, in those subjects,
there was the possibility that the eﬃcacy of treatment
could not be accurately assessed. Lastly, since the sterile
bicarbonate solution (Sublood-BS
￿)u s e da sr e p l a c e m e n t
ﬂuid in our SHDF contained a small amount of acetate, this
method was not completely acetate-free. Therefore, in order
to further validate the eﬀectiveness of acetate-free SHDF
for the treatment of critically ill patients with AKI, further
studies are needed; these should involve a comparison
of completely acetate-free dialysate and replacement ﬂuid,
with conventional dialysate and replacement ﬂuid both
containing a small amount of acetate.
5.Conclusion
Our results suggest that compared with conventional CRRT,
a strategy of more intensive renal support involving dailyInternational Journal of Nephrology 7
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Figure 2: Kaplan-Meier analysis of hospital survival rates after
CVVHDF versus SHDF. ( ): number of subjects alive.
postdilution SHDF with acetate-free dialysate may accelerate
the recovery of kidney function in critically ill patients with
AKI. The interruption of RRT by hemoﬁlter thrombosis and
catheter dysfunction was more frequent during CVVHDF
than during SHDF. These advantages suggest that acetate-
free dialysate may be preferable for patients with AKI. As
this study was performed on a small number of patients in a
single center, a randomized, prospective trial comparing the
eﬃcacies of acetate-free dialysate with conventional dialysate
in a large cohort of patients is warranted in order to
determine the relative impact of acetate-free dialysate and
SHDF on mortality.
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